Par's strategy is focused on building both our generic and branded businesses. This two-pronged approach is optimal because we can leverage intellectual capital and shared resources, maximize the value of our generics and branded portfolios, and provide greater transparency and predictability to investors.

Par's priorities in building and maintaining our Company as a successful business are to:

Generics Strategy:

• Focus on fewer, better products with higher barriers to entry
• Emphasize internal product development
• Leverage sales and marketing strength

Branded Strategy:

• Focus on in-licensing late-stage supportive care products
• Leverage our existing infrastructure
• Maximize Megace® ES sales growth and profitability